Skip to main content
Enterprise AI Analysis: Artificial intelligence utilization in cancer screening program across ASEAN: a scoping review

Enterprise AI Analysis

Artificial Intelligence Utilization in Cancer Screening Programs Across ASEAN

Cancer poses a significant health challenge in the ASEAN region, with varying screening approaches across member states. This scoping review explores the current landscape of cancer screening and the promising yet underexplored integration of Artificial Intelligence (AI) to enhance early detection, reduce costs, and improve patient outcomes.

Key Insights: AI in ASEAN Cancer Screening

0% Cancer cases preventable through primary prevention
0% AI studies in prospective clinical evaluation across ASEAN
0 AUC for AI-assisted oral cancer classification (Warin et al., Thailand)

Deep Analysis & Enterprise Applications

Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.

Cancer Screening Landscape in ASEAN

Organized Screening Opportunistic Screening
  • Brunei Darussalam, Singapore, Malaysia, Thailand
  • Population-based, systematic initiatives with regular intervals and targeted age groups.
  • Examples: Mammography for breast cancer, Pap smears for cervical cancer, FIT for colorectal cancer.
  • Myanmar, Laos, Cambodia, Vietnam, Philippines, Indonesia, Timor-Leste
  • Relies on individual healthcare provider recommendations, often targeting high-risk populations on a case-by-case basis.
  • Examples: Visual Inspection with Acetic Acid (VIA) for cervical cancer, mammography, HPV DNA testing.
Widespread Cervical Cancer Screening: Implemented by all ASEAN countries using both methods.

AI Integration & Performance in Cancer Screening

Study Selection Process for AI in Cancer Screening

Total records identified (n=781)
Record screening (n=302)
Record access for eligibility (n=41)
Studies Included in the study (n=14)
30.4% Increase in adenoma detection rates with AI-aided colonoscopy (from 24.3% in Singapore)
99.49% Sensitivity of AI-assisted cervicography interpretation system (Nurmaini et al., Indonesia)

Strategic Implications of AI in Cancer Screening

Strengths & Opportunities of AI in ASEAN Cancer Screening

Strengths: AI improves patient management by reducing unnecessary interventions and providing accurate diagnostic information. AI systems act as a "second radiologist" for early breast cancer diagnosis and AI-assisted chest radiography expands public screening uptake. Smartphone applications with AI detect pre-cancerous cervical lesions in real-time, benefiting remote populations.

Opportunities: AI can extend early detection and intervention to underserved populations, especially in rural and remote areas, through AI-integrated smartphone applications.

Weaknesses & Threats of AI in ASEAN Cancer Screening

Weaknesses: Inconsistent patient and clinician views on AI adoption, variability in reproducibility of AI-assisted screening, reliance on retrospective data (necessitating prospective studies), algorithmic bias in commercial AI software, potential for false positives leading to unnecessary investigations, and limited data for AI model development.

Threats: Diverse guidance on AI governance and ethical issues across the ASEAN region (accountability, transparency, privacy, diagnostic bias) pose significant challenges. Lack of comprehensive research on AI's real-world effect in clinical practice and individualized screening needs further exploration.

Calculate Your Potential AI Impact

Estimate the efficiency gains and cost savings AI can bring to your organization's screening and diagnostic processes.

Estimated Annual Savings $0
Annual Hours Reclaimed 0

Our Proven AI Implementation Roadmap

We guide you through every step of integrating AI, ensuring seamless adoption and measurable results for your enterprise.

Phase 1: Discovery & Strategy

We begin with an in-depth analysis of your current cancer screening programs, data infrastructure, and specific challenges within the ASEAN context. This phase defines clear objectives, identifies high-impact AI opportunities, and outlines a tailored strategic roadmap aligned with WHO 2030 targets and regional policies.

Phase 2: Pilot & Development

Leveraging secure, region-specific datasets, we develop and fine-tune AI models for your chosen cancer screening applications (e.g., breast, cervical, colorectal). This includes proof-of-concept testing, silent trials, and prospective clinical evaluations in a controlled environment to ensure accuracy and ethical compliance before broader deployment.

Phase 3: Integration & Scaling

AI solutions are integrated into your existing healthcare infrastructure, from hospital systems to smartphone applications for remote clinics. We provide comprehensive training for healthcare professionals and establish robust monitoring frameworks to track performance, refine models, and ensure successful scaling across diverse ASEAN settings, driving population-level impact.

Phase 4: Optimization & Governance

Continuous monitoring and iterative model optimization ensure sustained high performance. We work with you to establish strong governance guidelines, address accountability, transparency, and data privacy issues specific to the ASEAN regulatory landscape, ensuring long-term ethical and effective AI utilization in cancer screening.

Ready to Transform Cancer Screening with AI?

Connect with our experts to explore how tailored AI solutions can elevate your cancer screening programs, improve early detection, and enhance patient outcomes across the ASEAN region.

Ready to Get Started?

Book Your Free Consultation.

Let's Discuss Your AI Strategy!

Lets Discuss Your Needs


AI Consultation Booking